07h00-07h50 | Registration |
Opening Session by the Scientific Committee THERANOSTICS IN PROSTATE CANCER |
|||||||||
---|---|---|---|---|---|---|---|---|---|
08h00-08h10 |
|
PROSTATE CANCER I Primary staging |
|||
---|---|---|---|
Moderadores | Allan Santos, UNICAMP e MND | Wagner Matheus, UNICAMP | Antonio Zuliani de Oliveira, UNICAMP |
08h10-08h30 | How does nuclear medicine imaging impact patient management by the urologist? | Ubirajara Ferreira, UNICAMP | |
08h30-08h50 | Bone SPECT/CT? Fluoride-18F PET/CT? PSMA PET/CT? Which, when, and how? | Sérgio Almeida, Rede D´Dor, RJ | |
08h50-09h00 | PET/CT with PSMA-68Ga versus PET/CT with PSMA-18F | Camila Mosci, Hospital Vila Nova Star, SP | |
09h00-09h20 | PET PSMA in primary staging: when and why? | Onófrio Catalano, Massachussets General Hospital, USA | |
09h20-09h35 | Interactive Session: Take Home Message with clinical case discussion | ||
PSMA PET in primary staging | Presenter | Dalton Anjos, DASA, SP | |
Debater | Wagner Matheus, UNICAMP | ||
09h35-09h45 | Comments and questions from audience and moderators |
09h45-10h10 | Coffee Break |
PROSTATE CANCER II Diagnosis in biochemical recurrence and treatment response evaluation |
|||
---|---|---|---|
Moderadores | Elba Etchebehere, UNICAMP e MND | Ubirajara Ferreira, UNICAMP | Carlos Monti, Instituto do Radium |
10h10-10h30 | How does nuclear medicine imaging impact patient management by the oncologist? | André Moraes, Centro de Oncologia Campinas | |
10h30-10h45 | PET PSMA biochemical recurrence – when and why? | Onófrio Catalano, Massachussets General Hospital, USA | |
10h45-11h10 | PET/CT PSMA in treatment response evaluation. Advantages and limitations: is it worth it? | Mike Sathekge, University of Pretoria | |
11h10-11h20 | Cross fire: should I use PSMA PET to plan radiotherapy? | Yes | Eduardo Baldon, UNICAMP |
No | Antônio Zuliani, UNICAMP | ||
11h20-11h40 | Interactive Session: Take Home Message with clinical case discussion | ||
PSMA PET/CT Pitfalls | Presenter | Marcus Grigolon, Sírio Libanês, Brasília | |
Debater | Júlio Prestes, Hospital Sírio Libanês, SP | ||
PSMA PET in biochemical recurrence | Presenter | Marcelo Livorsi, Hospital Albert Einstein | |
Debater | Helena Saito, UNICAMP | ||
11h40-12h00 | Comments and questions from audience and moderators |
12h00-13h30 | Lunch break |
PROSTATE CANCER III Therapy with radiolabeled PSMA |
|||
---|---|---|---|
Moderadores | Mariana Lima, UNICAMP e MND | Fernandes Denardi, UNICAMP | André Moraes, Centro de Oncologia Campinas |
13h30-13h50 | PSMA PET/CT in oligometastatic disease | Elba Etchebehere, UNICAMP e MND | |
13h50-14h00 | PSMA PET/CT to define strategies and systemic treatment sequencing. | André Sasse, SonHe | |
14h00--14h30 | Clinical results of therapy with PSMA-177Lu/225Ac | Mike Sathekge, University of Pretoria, África do Sul | |
14h30-14h50 | Interactive Session: Take Home Message with clinical case discussion | ||
Therapy with 177Lu-PSMA and 225Ac-PSMA | Presenter | Mike Sathekge, University of Pretoria, África do Sul | |
Debater | André Moraes, Centro de Oncologia Campinas | ||
14h50--15h00 | Comments and questions from audience and moderators |
15h00-15h30 | Lunch break |
PROSTATE CANCER IV Therapy with 223Ra |
|||
---|---|---|---|
Moderadores | Celso Dario Ramos, UNICAMP e MND | Helena Saito, UNICAMP | Leonardo Reis, UNICAMP |
15h30-15h50 | 223Ra therapy: when to indicate? The nuclear medicine physician's perspective. | Flavia Lopes, Instituto Vilella-Pedras, RJ | |
15h50-16h10 | Controversies, interruption and re-treatment with 223Ra | Letícia Rigo, Beneficiência Portuguesa, SP | |
16h10-16h40 | Interactive Session: Take Home Message with clinical case discussion | ||
Monotherapy with 223Ra | Presenter | Letícia Rigo, Beneficiência Portuguesa, SP | |
Debater | Helena Saito, UNICAMP | ||
Combine therapy with 223Ra | Presenter | George Coura, USP | |
Debater | Leonardo Reis, UNICAMP | ||
16h40-16h50 | Comments and questions from audience and moderators |
19h30-23h30 | Symposium Celebration - Esquinica Vitória Hotel |